Zacks Small Cap Research

IN8bio, Inc (NASDAQ:INAB) presented updated results from its Phase I INB-100 trial at the European Hematology Association (EHA) Congress on June 13th in Madrid, Spain. Details of the presentation were provided in a press release and conference call after the close on June 13th, 2024 along with a slide deck to guide the discussion. Stakeholders have been eagerly awaiting the update on this trial since impressive data was presented back in December 2023 at the American Society of Hematology (ASH) Annual Meeting. Now six months later, all (N=10) of the treated leukemia patients achieved complete remission at the one-year mark. Of the 10 patients evaluated, 30% have achieved overall survival in excess of three years and one beyond four years. Only one patient has died, and this was attributed to idiopathic pulmonary fibrosis and not the experimental medication or leukemia. Multiple resources suggest that about 50% of patients relapse 12 months after hematopoietic stem cell transplant for hematological malignancies, highlighting the remarkable results that were achieved with no patients relapsing during the year long period.